Merck Animal Health Statement on SEQUIVITY™ Technology

Merck Animal Health fully supports the use of the SEQUIVITY™ Technology, a revolutionary, flexible, rapid and targeted vaccine production platform incorporating immuno-precision capabilities that protects against a wide range of disease-causing viral and bacterial pathogens in food and companion animals.

This process represents a technological advance within the company’s existing vaccine portfolio, because it allows the company to rapidly and precisely choose the gene of interest to produce specific antigens in order to make commercially available and/or custom-tailored vaccines. By using carefully selected gene sequences, the production platform enables targeted creation of a vaccine as needed for rapidly evolving pathogens, thereby offering a precise solution to evolving disease challenges.

The SEQUIVITY™ Technology production platform results in vaccines that contain RNA Particles (RP), which produce antigens to stimulate a protective immune response in animals. Where traditional vaccines can take years to develop using this technology, Merck Animal Health can provide a solution in a very short period of time.

Modern vaccine technologies or biotechnology vaccines are playing an ever-increasing role in pharmaceutical, vaccine and diagnostic discovery in veterinary medicine, contributing to improvements in the health and welfare of companion animals and food-producing animals. These technologies provide greater options for application, facilitating administration and enhancing animal welfare.

September 2020